Moving from Bench to Clinic to Deliver a Potentially Transformative Therapy for Duchenne Muscular Dystrophy
Join us for a Fireside Chat discussing Dyne’s Phase 1/2 clinical trial, DELIVER, evaluating DYNE-251 for the treatment of individuals with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.
Richard S. Finkel, MD
Director, Center for Experimental Neurotherapies
St. Jude Children’s Research Hospital
Ashish Dugar, PhD, MBA
Senior Vice President, Global Head of Medical Affairs
VP, Global Head of Patient Advocacy and KOL Engagement